Département d'Oncogénétique, Centre Jean Perrin, 63011 Clermont-Ferrand, France.
Service de Biochimie et Génétique Moléculaire, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.
Genes (Basel). 2023 Oct 25;14(11):1991. doi: 10.3390/genes14111991.
Hereditary predisposition to cancer affects about 3-5% of renal cancers. Testing criteria have been proposed in France for genetic testing of non-syndromic renal cancer. Our study explores the detection rates associated with our testing criteria. Using a comprehensive gene panel including 8 genes related to renal cancer and 50 genes related to hereditary predisposition to other cancers, we evaluated the detection rate of pathogenic variants in a cohort of 83 patients with suspected renal cancer predisposition. The detection rate was 7.2% for the renal cancer genes, which was 2.41-fold higher than the estimated 3% proportion of unselected kidney cases with inherited risk. Pathogenic variants in renal cancer genes were observed in 44.5% of syndromic cases, and in 2.7% of non-syndromic cases. Incidental findings were observed in , , and . was associated with renal cancer (OR at 7.14; 95% CI 1.74-29.6; < 0.003) in our study in comparison to the gnomAD control population. The detection rate in renal cancer genes was low in non-syndromic cases. Additional causal mechanisms are probably involved, and further research is required to find them. A study of the management of renal cancer risk for pathogenic variant carriers is needed.
遗传性癌症易感性影响约 3-5%的肾癌。法国已经提出了非综合征性肾癌基因检测的标准。我们的研究探讨了与我们的检测标准相关的检测率。使用包括 8 个与肾癌相关的基因和 50 个与其他癌症遗传易感性相关的基因的综合基因panel,我们评估了 83 名疑似肾癌遗传易感性患者队列中致病性变异的检出率。肾癌基因的检出率为 7.2%,比未选择的遗传性肾癌风险的 3%的估计比例高出 2.41 倍。在综合征病例中观察到肾癌基因的致病性变异占 44.5%,在非综合征病例中观察到 2.7%。在 、 、 和 中观察到偶然发现。与 gnomAD 对照人群相比,我们的研究发现 与肾癌相关(OR 为 7.14;95%CI 为 1.74-29.6; < 0.003)。在非综合征病例中,肾癌基因的检出率较低。可能涉及其他因果机制,需要进一步研究以找到它们。需要对 致病性变异携带者的肾癌风险进行管理研究。